Research progress of TIGIT in urinary system tumors
10.3969/j.issn.1009-8291.2024.11.016
- VernacularTitle:TIGIT在泌尿系统肿瘤中的研究进展
- Author:
Nuerdebieke DANIYAER
1
;
Zebibula ABUDUREHEMAN
1
;
Bingzhang QIAO
1
;
Rexiati MULATI
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
- Publication Type:Journal Article
- Keywords:
T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain;
kidney cancer;
bladder cancer;
prostate cancer;
urogenital system tumor;
programmed cell death protein-1
- From:
Journal of Modern Urology
2024;29(11):1012-1016
- CountryChina
- Language:Chinese
-
Abstract:
T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory receptor, which is highly expressed in a variety of malignant tumors.It can inhibit T cells and NK cells, and plays a key role in regulating immune response and tumor immune escape.TIGIT is closely related to the growth, metastasis and prognosis of urologic tumors, and its overexpression is associated with tumor progression and poor prognosis.Currently, TIGIT-based urologic tumors treatment strategies include monoclonal antibody therapy and combined immunotherapy, such as combination therapy with PD-1/PD-L1 and other drugs.Experimental and clinical studies on TIGIT are also being carried out and significant progress has been made.Therefore, TIGIT is expected to become a new target for immunotherapy and a biomarker for predicting the prognosis of patients with urologic tumors.This article reviews the research progress of TIGIT in urologic tumors.
